The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM

Standard

The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM. / Piroddi, Nicoletta; Witjas-Paalberends, E Rosalie; Ferrara, Claudia; Ferrantini, Cecilia; Vitale, Giulia; Scellini, Beatrice; Wijnker, Paul J M; Sequiera, Vasco; Dooijes, Dennis; Dos Remedios, Cristobal; Schlossarek, Saskia; Leung, Man Ching; Messer, Andrew; Ward, Douglas G; Biggeri, Annibale; Tesi, Chiara; Carrier, Lucie; Redwood, Charles S; Marston, Steven B; van der Velden, Jolanda; Poggesi, Corrado.

In: J GEN PHYSIOL, Vol. 151, No. 1, 07.01.2019, p. 18-29.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Piroddi, N, Witjas-Paalberends, ER, Ferrara, C, Ferrantini, C, Vitale, G, Scellini, B, Wijnker, PJM, Sequiera, V, Dooijes, D, Dos Remedios, C, Schlossarek, S, Leung, MC, Messer, A, Ward, DG, Biggeri, A, Tesi, C, Carrier, L, Redwood, CS, Marston, SB, van der Velden, J & Poggesi, C 2019, 'The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM', J GEN PHYSIOL, vol. 151, no. 1, pp. 18-29. https://doi.org/10.1085/jgp.201812160

APA

Piroddi, N., Witjas-Paalberends, E. R., Ferrara, C., Ferrantini, C., Vitale, G., Scellini, B., Wijnker, P. J. M., Sequiera, V., Dooijes, D., Dos Remedios, C., Schlossarek, S., Leung, M. C., Messer, A., Ward, D. G., Biggeri, A., Tesi, C., Carrier, L., Redwood, C. S., Marston, S. B., ... Poggesi, C. (2019). The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM. J GEN PHYSIOL, 151(1), 18-29. https://doi.org/10.1085/jgp.201812160

Vancouver

Piroddi N, Witjas-Paalberends ER, Ferrara C, Ferrantini C, Vitale G, Scellini B et al. The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM. J GEN PHYSIOL. 2019 Jan 7;151(1):18-29. https://doi.org/10.1085/jgp.201812160

Bibtex

@article{ee7126d0cedf48a0856605fe887f3286,
title = "The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM",
abstract = "Hypertrophic cardiomyopathy (HCM) is a genetic form of left ventricular hypertrophy, primarily caused by mutations in sarcomere proteins. The cardiac remodeling that occurs as the disease develops can mask the pathogenic impact of the mutation. Here, to discriminate between mutation-induced and disease-related changes in myofilament function, we investigate the pathogenic mechanisms underlying HCM in a patient carrying a homozygous mutation (K280N) in the cardiac troponin T gene (TNNT2), which results in 100% mutant cardiac troponin T. We examine sarcomere mechanics and energetics in K280N-isolated myofibrils and demembranated muscle strips, before and after replacement of the endogenous troponin. We also compare these data to those of control preparations from donor hearts, aortic stenosis patients (LVHao), and HCM patients negative for sarcomeric protein mutations (HCMsmn). The rate constant of tension generation following maximal Ca2+ activation (kACT) and the rate constant of isometric relaxation (slow kREL) are markedly faster in K280N myofibrils than in all control groups. Simultaneous measurements of maximal isometric ATPase activity and Ca2+-activated tension in demembranated muscle strips also demonstrate that the energy cost of tension generation is higher in the K280N than in all controls. Replacement of mutant protein by exchange with wild-type troponin in the K280N preparations reduces kACT, slow kREL, and tension cost close to control values. In donor myofibrils and HCMsmn demembranated strips, replacement of endogenous troponin with troponin containing the K280N mutant increases kACT, slow kREL, and tension cost. The K280N TNNT2 mutation directly alters the apparent cross-bridge kinetics and impairs sarcomere energetics. This result supports the hypothesis that inefficient ATP utilization by myofilaments plays a central role in the pathogenesis of the disease.",
keywords = "Journal Article",
author = "Nicoletta Piroddi and Witjas-Paalberends, {E Rosalie} and Claudia Ferrara and Cecilia Ferrantini and Giulia Vitale and Beatrice Scellini and Wijnker, {Paul J M} and Vasco Sequiera and Dennis Dooijes and {Dos Remedios}, Cristobal and Saskia Schlossarek and Leung, {Man Ching} and Andrew Messer and Ward, {Douglas G} and Annibale Biggeri and Chiara Tesi and Lucie Carrier and Redwood, {Charles S} and Marston, {Steven B} and {van der Velden}, Jolanda and Corrado Poggesi",
note = "{\textcopyright} 2018 Piroddi et al.",
year = "2019",
month = jan,
day = "7",
doi = "10.1085/jgp.201812160",
language = "English",
volume = "151",
pages = "18--29",
journal = "J GEN PHYSIOL",
issn = "0022-1295",
publisher = "Rockefeller University Press",
number = "1",

}

RIS

TY - JOUR

T1 - The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM

AU - Piroddi, Nicoletta

AU - Witjas-Paalberends, E Rosalie

AU - Ferrara, Claudia

AU - Ferrantini, Cecilia

AU - Vitale, Giulia

AU - Scellini, Beatrice

AU - Wijnker, Paul J M

AU - Sequiera, Vasco

AU - Dooijes, Dennis

AU - Dos Remedios, Cristobal

AU - Schlossarek, Saskia

AU - Leung, Man Ching

AU - Messer, Andrew

AU - Ward, Douglas G

AU - Biggeri, Annibale

AU - Tesi, Chiara

AU - Carrier, Lucie

AU - Redwood, Charles S

AU - Marston, Steven B

AU - van der Velden, Jolanda

AU - Poggesi, Corrado

N1 - © 2018 Piroddi et al.

PY - 2019/1/7

Y1 - 2019/1/7

N2 - Hypertrophic cardiomyopathy (HCM) is a genetic form of left ventricular hypertrophy, primarily caused by mutations in sarcomere proteins. The cardiac remodeling that occurs as the disease develops can mask the pathogenic impact of the mutation. Here, to discriminate between mutation-induced and disease-related changes in myofilament function, we investigate the pathogenic mechanisms underlying HCM in a patient carrying a homozygous mutation (K280N) in the cardiac troponin T gene (TNNT2), which results in 100% mutant cardiac troponin T. We examine sarcomere mechanics and energetics in K280N-isolated myofibrils and demembranated muscle strips, before and after replacement of the endogenous troponin. We also compare these data to those of control preparations from donor hearts, aortic stenosis patients (LVHao), and HCM patients negative for sarcomeric protein mutations (HCMsmn). The rate constant of tension generation following maximal Ca2+ activation (kACT) and the rate constant of isometric relaxation (slow kREL) are markedly faster in K280N myofibrils than in all control groups. Simultaneous measurements of maximal isometric ATPase activity and Ca2+-activated tension in demembranated muscle strips also demonstrate that the energy cost of tension generation is higher in the K280N than in all controls. Replacement of mutant protein by exchange with wild-type troponin in the K280N preparations reduces kACT, slow kREL, and tension cost close to control values. In donor myofibrils and HCMsmn demembranated strips, replacement of endogenous troponin with troponin containing the K280N mutant increases kACT, slow kREL, and tension cost. The K280N TNNT2 mutation directly alters the apparent cross-bridge kinetics and impairs sarcomere energetics. This result supports the hypothesis that inefficient ATP utilization by myofilaments plays a central role in the pathogenesis of the disease.

AB - Hypertrophic cardiomyopathy (HCM) is a genetic form of left ventricular hypertrophy, primarily caused by mutations in sarcomere proteins. The cardiac remodeling that occurs as the disease develops can mask the pathogenic impact of the mutation. Here, to discriminate between mutation-induced and disease-related changes in myofilament function, we investigate the pathogenic mechanisms underlying HCM in a patient carrying a homozygous mutation (K280N) in the cardiac troponin T gene (TNNT2), which results in 100% mutant cardiac troponin T. We examine sarcomere mechanics and energetics in K280N-isolated myofibrils and demembranated muscle strips, before and after replacement of the endogenous troponin. We also compare these data to those of control preparations from donor hearts, aortic stenosis patients (LVHao), and HCM patients negative for sarcomeric protein mutations (HCMsmn). The rate constant of tension generation following maximal Ca2+ activation (kACT) and the rate constant of isometric relaxation (slow kREL) are markedly faster in K280N myofibrils than in all control groups. Simultaneous measurements of maximal isometric ATPase activity and Ca2+-activated tension in demembranated muscle strips also demonstrate that the energy cost of tension generation is higher in the K280N than in all controls. Replacement of mutant protein by exchange with wild-type troponin in the K280N preparations reduces kACT, slow kREL, and tension cost close to control values. In donor myofibrils and HCMsmn demembranated strips, replacement of endogenous troponin with troponin containing the K280N mutant increases kACT, slow kREL, and tension cost. The K280N TNNT2 mutation directly alters the apparent cross-bridge kinetics and impairs sarcomere energetics. This result supports the hypothesis that inefficient ATP utilization by myofilaments plays a central role in the pathogenesis of the disease.

KW - Journal Article

U2 - 10.1085/jgp.201812160

DO - 10.1085/jgp.201812160

M3 - SCORING: Journal article

C2 - 30578328

VL - 151

SP - 18

EP - 29

JO - J GEN PHYSIOL

JF - J GEN PHYSIOL

SN - 0022-1295

IS - 1

ER -